Paloma Partners’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Paloma Partners’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12,010	Closed	-$115K	–	2426
2019 Q2	$115K	Buy	+12,010	New	+$221K	﹤0.01%	1611
2019 Q1	–	Sell	-1,465	Closed	-$33K	–	2061
2018 Q4	$33K	Buy	+1,465	New	+$57.3K	﹤0.01%	1177
2018 Q2	–	Sell	-739	Closed	-$45K	–	2393
2018 Q1	$45K	Sell	739 -930	-56%	-$81.6K	﹤0.01%	1863
2017 Q4	$210K	Buy	+1,669	New	+$214K	﹤0.01%	1715
2016 Q2	–	Sell	-611	Closed	-$57K	–	2414
2016 Q1	$57K	Sell	611 -886	-59%	-$88.5K	﹤0.01%	1795
2015 Q4	$300K	Buy	+1,497	New	+$299K	0.01%	1327

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Paloma Partners's TTPH Position: Q3 2019 in Review

Paloma Partners sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 12,010 shares — an estimated $115K sold.

Paloma Partners first reported a position in TTPH in Q4 2015 and held it in 6 quarters. The position peaked at $300K in Q4 2015. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

Paloma Partners reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Paloma Partners sold 12,010 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $115K.
Paloma Partners first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 6 quarters.
Paloma Partners's Tetraphase Pharmaceuticals, Inc. position peaked at $300K in Q4 2015.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.